Therapeutic Potential of the Novel GLP-1 Receptor Agonist Semaglutide in Alcohol Use Disorder

Abstract

Alcohol use disorder (AUD) is a prevalent neuropsychiatric disorder with serious health and social consequences. However, few licensed and successful pharmacotherapies exist for heterogeneous and complex disorders such as AUD, and these are poorly utilized. Preclinical and clinical findings suggest that the glucagon-like peptide-1 (GLP-1) system, a gut-brain peptide, is involved in the neurobiology of addictive behaviors. Additionally, the GLP-1 receptor (GLP-1R) has become a promising target for the treatment of AUD. Semaglutide, a novel GLP-1R agonist, has received clinical approval to treat type 2 diabetes in both subcutaneous and oral dosage forms. Studies have shown that it significantly reduces alcohol consumption and relapse of alcohol addiction in rats, suggesting its potential effectiveness for treating alcohol abuse in humans, particularly in overweight patients with AUDs. However, the use of semaglutide is associated with potential risks, such as gallbladder disease and clinical complications associated with delayed gastric emptying. This review evaluates the safety of semaglutide to inform its wider clinical application. Further extensive and in-depth studies on semaglutide are needed to reveal additional valuable clinical benefits.

Keywords

alcohol use disorder - GLP-1 - GLP-1RA - semaglutide - semaglutide safety

^* Tingting Liu and Fuqiang Shi contributed equally to this work and they both join first authorship.

Publication History

Received: 05 January 2025

Accepted: 24 February 2025

Article published online:
14 April 2025

• References

• 1 Degenhardt L, Charlson F, Ferrari A. et al. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Psychiatry 2018; 5: 987-1012
• 2 World Health Organization. Global status report on alcohol and health 2018. Geneva: World Health Organization; 2018
• 3 Grant BF, Goldstein RB, Saha TD. et al. Epidemiology of DSM-5 alcohol use disorder: Results from the National Epidemiologic Survey on Alcohol and Related Conditions III. JAMA Psychiatry 2015; 72: 757-766
• 4 Klausen MK, Thomsen M, Wortwein G. et al. The role of glucagon-like peptide 1 (GLP-1) in addictive disorders. Br J Pharmacol 2022; 179: 625-641
• 5 American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. 2013
• 6 Koob GF, Volkow ND. Neurobiology of addiction: A neurocircuitry analysis. Lancet Psychiatry 2016; 3: 760-773
• 7 Carvalho AF, Heilig M, Perez A. et al. Alcohol use disorders. Lancet Lond Engl 2019; 394: 781-792
• 8 Jerlhag E. GLP-1 signaling and alcohol-mediated behaviors; preclinical and clinical evidence. Neuropharmacology 2018; 136: 343-349
• 9 Nauck MA, Quast DR, Wefers J. et al. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Mol Metab 2021; 46: 101102
• 10 Wilding JPH, Batterham RL, Calanna S. et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021; 384: 989-1002
• 11 Bucheit JD, Pamulapati LG, Carter N. et al. Oral semaglutide: A review of the first oral glucagon-like peptide 1 receptor agonist. Diabetes Technol Ther 2020; 22: 10-18
• 12 Chuong V, Farokhnia M, Khom S. et al. The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission. JCI Insight 2023; 8: e170671
• 13 Aranäs C, Edvardsson CE, Shevchouk OT. et al. Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats. EBioMedicine 2023; 93: 104642
• 14 Taşçı SK, Bingöl SA. GLP-1 Localisation and proglucagon gene expression in healthy and diabetic mouse ileum. J Vet Res 2018; 62: 237-242
• 15 Merchenthaler I, Lane M, Shughrue P. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol 1999; 403: 261-280
• 16 Alhadeff AL, Rupprecht LE, Hayes MR. GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake. Endocrinology 2012; 153: 647-658
• 17 Cornu M, Yang J-Y, Jaccard E. et al. Glucagon-like peptide-1 protects β-cells against apoptosis by increasing the activity of an Igf-2/Igf-1 receptor autocrine loop. Diabetes 2009; 58: 1816-1825
• 18 Zummo FP, Cullen KS, Honkanen-Scott M. et al. Glucagon-like peptide 1 protects pancreatic β-cells from death by increasing autophagic flux and restoring lysosomal function. Diabetes 2017; 66: 1272-1285
• 19 Krieger J-P, Langhans W, Lee SJ. Vagal mediation of GLP-1’s effects on food intake and glycemia. Physiol Behav 2015; 152: 372-380
• 20 Abegg K, Schiesser M, Lutz TA. et al. Acute peripheral GLP-1 receptor agonism or antagonism does not alter energy expenditure in rats after Roux-en-Y gastric bypass. Physiol Behav 2013; 121: 70-78
• 21 Guerrero-Hreins E, Goldstone AP, Brown RM. et al. The therapeutic potential of GLP-1 analogues for stress-related eating and role of GLP-1 in stress, emotion and mood: A review. Prog Neuropsychopharmacol Biol Psychiatry 2021; 110: 110303
• 22 Hu D, Ch M, Ra P. Type 2 diabetes--therapy with dipeptidyl peptidase IV inhibitors. Biochim Biophys Acta 2005; 1751
• 23 Jerlhag E. The therapeutic potential of glucagon-like peptide-1 for persons with addictions based on findings from preclinical and clinical studies. Front Pharmacol 2023; 14: 1063033
• 24 Kolterman OG, Kim DD, Shen L. et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005; 62: 173-181
• 25 Knudsen LB, Nielsen PF, Huusfeldt PO. et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000; 43: 1664-1669
• 26 Aroda VR, DeYoung MB. Clinical implications of exenatide as a twice-daily or once-weekly therapy for type 2 diabetes. Postgrad Med 2011;
• 27 Finan B, Clemmensen C, Müller TD. Emerging opportunities for the treatment of metabolic diseases: Glucagon-like peptide-1 based multi-agonists. Mol Cell Endocrinol 2015; 418: 42-54
• 28 Barrington P, Chien JY, Tibaldi F. et al. LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects. Diabetes Obes Metab 2011; 13: 434-438
• 29 Bush MA, Matthews JE, Boever EHD. et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects. Diabetes Obes Metab 2009; 11: 498-505
• 30 Marso SP, Bain SC, Consoli A. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375: 1834-1844
• 31 Xia L, Shen T, Dong W. et al. Comparative efficacy and safety of 8 GLP-1RAs in patients with type 2 diabetes: A network meta-analysis. Diabetes Res Clin Pract 2021; 177: 108904
• 32 Andersen A, Lund A, Knop FK. et al. Glucagon-like peptide 1 in health and disease. Nat Rev Endocrinol 2018; 14: 390-403
• 33 Deacon CF, Nauck MA, Toft-Nielsen M. et al. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995; 44: 1126-1131
• 34 Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol 2019; 10
• 35 Mahapatra MK, Karuppasamy M, Sahoo BM. Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes. Rev Endocr Metab Disord 2022; 23: 521-539
• 36 Lau J, Bloch P, Schäffer L. et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem 2015; 58: 7370-7380
• 37 Niman S, Hardy J, Goldfaden RF. et al. A review on the efficacy and safety of oral semaglutide. Drugs RD 2021; 21: 133-148
• 38 Olds J, Milner P. Positive reinforcement produced by electrical stimulation of septal area and other regions of rat brain. J Comp Physiol Psychol 1954; 47: 419-427
• 39 Drevets WC, Gautier C, Price JC. et al. Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biol Psychiatry 2001; 49: 81-96
• 40 Marty VN, Farokhnia M, Munier JJ. et al. Long-acting glucagon-like peptide-1 receptor agonists suppress voluntary alcohol intake in male wistar rats. Front Neurosci 2020; 14: 599646
• 41 Quddos F, Hubshman Z, Tegge A. et al. Semaglutide and tirzepatide reduce alcohol consumption in individuals with obesity. Sci Rep 2023; 13: 20998
• 42 Fink-Jensen A, Wörtwein G, Klausen MK. et al. Effect of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide on alcohol consumption in alcohol-preferring male vervet monkeys. Psychopharmacology (Berl) 2024;
• 43 Granhall C, Donsmark M, Blicher TM. et al. Safety and pharmacokinetics of single and multiple ascending doses of the novel oral human GLP-1 analogue, oral semaglutide, in healthy subjects and subjects with type 2 diabetes. Clin Pharmacokinet 2019; 58
• 44 Andreadis P, Karagiannis T, Malandris K. et al. Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetes Obes Metab 2018; 20: 2255-2263
• 45 Fadini GP, Sarangdhar M, Avogaro A. Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA Adverse Event Reporting System. BMJ Open Diabetes Res Care 2018; 6: e000475
• 46 Rehfeld JF, Knop FK, Asmar A. et al. Cholecystokinin secretion is suppressed by glucagon-like peptide-1: Clue to the mechanism of the adverse gallbladder events of GLP-1-derived drugs. Scand J Gastroenterol 2018; 53: 1429-1432
• 47 He L, Wang J, Ping F. et al. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: A systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med 2022; 182: 513-519
• 48 Mahapatra MK, Karuppasamy M, Sahoo BM. Therapeutic potential of semaglutide, a newer GLP-1 receptor agonist, in abating obesity, non-alcoholic steatohepatitis and neurodegenerative diseases: A narrative review. Pharm Res 2022; 39: 1233-1248